Cytomegalovirus encephalitis/retinitis in allogeneic haematopoietic stem cell transplant recipient treated successfully with combination of cidofovir and foscarnet.
We report an 18-yr-old female patient with repeated CMV reactivations after HSCT treated by several pre-emptive courses of virostatic therapy. Seven months after HSCT, she developed CMV encephalitis/retinitis. Initial therapy with GCV and hyperimmune globulin failed, and later on GCV-resistant strain was detected. Continual increase of CMV DNA in peripheral blood led us to combined therapy with CDV and FCV, which was successful and free of severe renal toxicity. To our best knowledge, this is the first reported case of successful CMV treatment with a combination of CDV and FCV.
Hubacek
Petr
P
Motol University Hospital, Prague, Czech Republic. petr.hubacek@lfmotol.cuni.cz
Keslova
Petra
P
Formankova
Renata
R
Pochop
Pavel
P
Cinek
Ondrej
O
Zajac
Miroslav
M
Lochmanova
Jana
J
Stary
Jan
J
Sedlacek
Petr
P
D000293:Adolescent; D000998:Antiviral Agents / Q000627:therapeutic use*; D000077404:Cidofovir; D003586:Cytomegalovirus Infections / Q000150:complications / Q000188:drug therapy* / Q000209:etiology*; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018792:Encephalitis, Viral / Q000150:complications / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D017245:Foscarnet / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000628:therapy; D063065:Organophosphonates / Q000627:therapeutic use*; D012173:Retinitis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology*; D016896:Treatment Outcome
D000998:Antiviral Agents; D063065:Organophosphonates; D017245:Foscarnet; D003596:Cytosine; D000077404:Cidofovir